Benzodiazepine Overdose

Benzodiazepine overdose causes CNS depression through GABA-A receptor agonism, ranging from drowsiness to coma, with the primary life-threatening mechanism being respiratory compromise from loss of protective airway reflexes. Isolated benzodiazepine poisoning rarely causes life-threatening hypoventilation or hemodynamic instability — most fatalities involve coingestants (opioids, alcohol, other CNS depressants). [1-2] Management is primarily supportive care with airway management; flumazenil is reserved for select low-risk cases. [1-2]

• What was ingested? Specific benzodiazepine (short-acting: alprazolam, midazolam vs. long-acting: diazepam, clonazepam), amount, formulation (immediate vs. extended release)
• Time of ingestion — critical for GI decontamination decisions and predicting peak effects
• Intentional vs. accidental — suicidal intent, recreational use, pediatric exploratory ingestion, iatrogenic (procedural sedation)
• Coingestants — opioids, alcohol, TCAs, other sedative-hypnotics, anticonvulsants. This is the single most important historical question, as mixed overdose dramatically changes morbidity/mortality [1-2]
• Chronic benzodiazepine use — tolerance and dependence status (critical for flumazenil decision-making) [1][3]
• Symptom progression — drowsiness → confusion → slurred speech → ataxia → unresponsiveness
• Important negatives: Chest pain, seizure activity, vomiting, head trauma

• Respiratory depression (RR <12, SpO₂ <90%, apnea) — the primary mechanism of death [1-2]
• Hemodynamic instability — markedly abnormal BP or HR strongly suggests coingestant involvement [4-5]
• Coma / GCS ≤8 — loss of airway protective reflexes, aspiration risk
• Seizures — not expected with isolated benzodiazepine OD; suggests coingestant (TCA, tramadol) or withdrawal
• Paradoxical agitation — rare but can occur (agitation, violence, impulsivity) [4][6]
• Hypothermia — prolonged immobilization
• Markedly abnormal vital signs in any direction raise concern for polypharmacy overdose [4-5]

Antidote — Flumazenil (competitive GABA-A antagonist): [3]

• Dosing for overdose: 0.2 mg IV over 30 seconds → if no response after 30 sec, give 0.3 mg → then 0.5 mg doses at 1-minute intervals up to 3 mg total [3]
• Duration of action: 45–90 minutes; resedation is common with long-acting benzodiazepines [3]
• Maximum: 3 mg in any one hour; repeat doses at ≥20-minute intervals [3]

Flumazenil contraindications / high-risk situations: [1-3]

• Chronic benzodiazepine dependence (risk of refractory withdrawal seizures)
• Suspected TCA or other proconvulsant coingestant
• Seizure disorder treated with benzodiazepines
• Undifferentiated coma with unknown history
• Signs of cyclic antidepressant toxicity (wide QRS, mydriasis, twitching) [3]

Safe flumazenil use is limited to: [1-2]

• Iatrogenic oversedation during procedural sedation
• Pediatric exploratory ingestions
• Known isolated benzodiazepine ingestion with no chronic use

Naloxone — should be administered empirically if opioid coingestant is suspected; opioid poisoning is more common and causes more significant respiratory depression, and naloxone has a better safety profile than flumazenil [1-2]

• NPO if altered mental status or risk of aspiration
• No specific dietary triggers or long-term dietary management relevant to acute overdose
• Hydration with IV fluids as part of supportive care [4]

• Neuro: Level of consciousness, confusion, dysarthria, ataxia, seizure activity
• Respiratory: Dyspnea, apnea, snoring/stridor (airway obstruction)
• GI: Nausea, vomiting (aspiration risk), last oral intake
• Psych: Suicidal ideation, self-harm intent, psychiatric history
• MSK: Prolonged immobilization → rhabdomyolysis, compartment syndrome
• Skin: Track marks (IV drug use), transdermal patches, cyanosis [7]

• EMS report — scene findings, pill bottles, drug paraphernalia, suicide note
• Family/friends — medication access, recent behavioral changes, substance use history, prior overdose attempts
• Pharmacy records — prescribed benzodiazepines, opioids, TCAs, anticonvulsants
• Psychiatric history — prior suicide attempts, current mental health treatment
• Family history of substance use disorder or psychiatric illness may inform disposition planning

• Polypharmacy — concurrent opioid prescriptions (the leading risk factor for fatal BZD overdose) [1-2]
• Substance use disorder — alcohol, opioids, illicit drug use
• Elderly patients — increased sensitivity, prolonged metabolism, fall risk
• Hepatic impairment — prolonged benzodiazepine metabolism (especially diazepam, chlordiazepoxide)
• Chronic benzodiazepine use — tolerance leading to dose escalation
• Psychiatric comorbidities — depression, anxiety disorders, prior suicide attempts
• Respiratory comorbidities — COPD, OSA increase vulnerability to respiratory depression

• Opioid overdose — miosis, more profound respiratory depression, responds to naloxone
• Alcohol intoxication — odor of alcohol, elevated BAL; frequently coingested
• TCA overdose — wide QRS, anticholinergic signs (mydriasis, dry mucosa, tachycardia, urinary retention)
• GHB/barbiturate overdose — similar sedation profile; barbiturates cause more cardiovascular depression
• Hypoglycemia — check point-of-care glucose immediately
• Hepatic encephalopathy — asterixis, elevated ammonia
• Structural CNS pathology — stroke, intracranial hemorrhage (focal deficits, asymmetric exam)
• Postictal state — tongue laceration, incontinence, witnessed seizure
• Carbon monoxide poisoning — headache, cherry-red skin, environmental exposure
• Hypothyroidism/myxedema coma — hypothermia, bradycardia, delayed relaxation of reflexes

• Prior overdose attempts or self-harm
• Chronic benzodiazepine prescription (duration, dose — critical for flumazenil risk assessment) [1][3]
• Seizure disorder (flumazenil contraindication) [3]
• Psychiatric diagnoses and current medications (especially TCAs, SSRIs)
• Hepatic or renal disease (affects drug metabolism and clearance)
• Respiratory disease (COPD, OSA)
• Substance use history including alcohol use disorder

• Vitals: Respiratory rate (most critical), SpO₂, BP, HR, temperature. Markedly abnormal vitals suggest coingestant [4-5]
• Neuro: GCS, pupil size and reactivity (benzodiazepines typically cause normal to mildly dilated pupils — miosis suggests opioid, mydriasis suggests anticholinergic), speech, gait if ambulatory [7]
• Airway: Patency, gag reflex, secretions, stridor
• Respiratory: Rate, depth, pattern, breath sounds (aspiration)
• Cardiovascular: Rate, rhythm, perfusion
• Skin: Color (cyanosis), temperature, moisture, track marks, patches [7]
• Musculoskeletal: Tone (expect hypotonia), reflexes (expect diminished) [4-5]
• GI: Bowel sounds (absent in anticholinergic toxidrome)
• Expected findings in isolated BZD OD: Drowsiness, dysarthria, ataxia, hypotonia, diminished reflexes, normal pupils, relatively preserved hemodynamics [4]

• Point-of-care glucose — rule out hypoglycemia immediately
• Serum acetaminophen and salicylate levels — standard in all intentional overdoses to rule out occult coingestant
• Ethanol level
• BMP — electrolytes, renal function, glucose, anion gap
• CBC — baseline
• VBG/ABG — if respiratory depression present (assess for hypercarbia, hypoxemia)
• Urine drug screen — qualitative; note that many newer benzodiazepines (clonazepam, lorazepam, alprazolam) may not be detected on standard immunoassays
• Serum benzodiazepine levels — generally not clinically useful and not routinely recommended; management is guided by clinical presentation
• Hepatic function — if hepatotoxic coingestant suspected
• CK — if prolonged immobilization (rhabdomyolysis risk)
• Lactate — if hemodynamic instability [7]

• Chest X-ray — if aspiration suspected, intubated, or respiratory distress
• CT head — if altered mental status out of proportion to expected benzodiazepine effect, focal neurologic findings, or history of trauma/fall
• Routine imaging is not necessary for straightforward isolated benzodiazepine overdose with expected clinical trajectory

• Glasgow Coma Scale — serial assessments to document and communicate level of impairment [7]
• Capnography (ETCO₂) — continuous monitoring for hypoventilation, especially useful in patients who maintain SpO₂ on supplemental O₂ but are hypoventilating
• Poison Control consultation (1-800-222-1222) — recommended for all significant overdoses [4]
• Toxicology consultation — for complex mixed overdoses, flumazenil decision-making, or refractory cases [8]

• Obtain ECG in all intentional overdoses — primarily to evaluate for coingestant toxicity [7]
• Isolated benzodiazepine OD: ECG is typically normal or shows mild sinus bradycardia
• Critical findings suggesting coingestant:
  • Wide QRS (>100 ms) → TCA toxicity (sodium channel blockade) — flumazenil contraindicated [3]
  • Prolonged QTc → antipsychotic, methadone, or other QT-prolonging drug
  • Bradycardia → beta-blocker, calcium channel blocker, opioid coingestant
• Flumazenil may precipitate dysrhythmias (SVT, ventricular dysrhythmias, asystole) in the presence of dysrhythmogenic coingestants [1-2]

Severity stratification

• Mild: Drowsiness, confusion, dysarthria, ataxia — maintains airway and adequate ventilation
• Moderate: Significant somnolence, hypotonia, diminished reflexes — requires close monitoring
• Severe: Coma, respiratory depression, loss of airway reflexes — requires airway intervention [4-5]

Key clinical pearl: Isolated benzodiazepine overdose is rarely fatal in adults. If a patient presents with significant hemodynamic instability, profound respiratory depression, or cardiac arrest, always suspect coingestants — particularly opioids, alcohol, or TCAs. [1-2] The clinical course of isolated BZD OD is generally benign with supportive care alone. [8]

Initial stabilization (ABCs)

• Airway: Positioning, jaw thrust, suctioning. Bag-mask ventilation for apnea/hypoventilation. Endotracheal intubation if unable to maintain airway or ventilation [1]
• Breathing: Supplemental O₂, continuous pulse oximetry and capnography
• Circulation: IV access, IV fluids, cardiac monitoring

GI decontamination

• Activated charcoal (1 g/kg, max 50–100 g) — may be considered if presenting within 1–2 hours of a significant ingestion with intact/protected airway. Not a benzodiazepine-specific recommendation in the 2026 Clinical Toxicology Recommendations Collaborative guidelines, but benzodiazepines are generally well-adsorbed by charcoal [8-10]
• No role for gastric lavage, ipecac, or whole bowel irrigation in isolated BZD overdose

Antidote

• Flumazenil — only in carefully selected low-risk patients (see Medications section above) [1-3]
• Naloxone 0.4–2 mg IV — administer empirically if opioid coingestant suspected [1-2]

Supportive care

• Continuous cardiorespiratory monitoring
• DVT prophylaxis if prolonged immobilization [8]
• Aspiration precautions (lateral decubitus positioning if not intubated)
• Rewarming if hypothermic
• IV fluid resuscitation for hypotension

Benzodiazepines are not significantly removed by dialysis [11]

Admission / ICU criteria

• Endotracheal intubation or mechanical ventilation
• Persistent respiratory depression or hemodynamic instability
• Significant coingestant requiring monitoring (TCA, opioid, etc.)
• Recurrent sedation after flumazenil (resedation risk) [3]
• Suicidal intent requiring psychiatric evaluation under safe conditions

Observation criteria

• Moderate sedation with stable vitals — observe until clinically sober and ambulatory (typically 4–6 hours for short-acting agents, longer for long-acting)
• Post-flumazenil monitoring for at least 2 hours for resedation [3]

Discharge criteria

• Alert, oriented, ambulatory with stable vitals
• Adequate respiratory function off supplemental O₂
• Able to tolerate oral intake
• Psychiatric clearance if intentional overdose
• Safe disposition plan (reliable adult supervision)

Specialist consultation triggers

• Toxicology — complex mixed overdose, flumazenil decision-making, refractory cases [8]
• Psychiatry — all intentional overdoses before discharge
• Critical care — intubated patients, hemodynamic instability

Follow-up timing

• PCP within 48–72 hours
• Psychiatry follow-up within 1 week if intentional overdose
• Substance use counseling referral if applicable [12-13]

Return precautions — instruct patient/family to return immediately for:

• Recurrent drowsiness or difficulty waking (resedation, especially with long-acting agents)
• Difficulty breathing or noisy breathing
• Confusion or altered behavior
• Vomiting (aspiration risk)
• Seizures

Patient counseling

• Avoid alcohol and other CNS depressants
• Discuss safe medication storage (especially with children in the home)
• If prescribed benzodiazepines chronically, do not abruptly discontinue — risk of withdrawal seizures [12-13]
• Naloxone co-prescription if concurrent opioid use
• Expected recovery: isolated BZD overdose typically resolves within 6–24 hours depending on the agent's half-life

1. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Lavonas EJ, Akpunonu PD, Arens AM, et al. Circulation. 2023.

2. Part 10: Adult and Pediatric Special Circumstances of Resuscitation: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Cao D, Arens AM, Chow SL, et al. Circulation. 2025.

3. FDA Drug Label. — Updated date: 2020-01-03. Food and Drug Administration.

4. FDA Drug Label. — Updated date: 2025-07-09. Food and Drug Administration.

5. FDA Drug Label. — Updated date: 2026-01-29. Food and Drug Administration.

6. FDA Drug Label. — Updated date: 2024-04-09. Food and Drug Administration.

7. Acute Medication Poisoning. — Vega IL, Griswold MK, Laskey D. American Family Physician. 2024.

8. Strategies for the Treatment of Acute Benzodiazepine Toxicity in a Clinical Setting: The Role of Antidotes. — Zamani N, Hassanian-Moghaddam H, Zamani N. Expert Opinion on Drug Metabolism & Toxicology. 2022.

9. Recommendations From the Clinical Toxicology Recommendations Collaborative on the Administration of Activated Charcoal in Acute Oral Overdose. — Hoegberg LCG, Gosselin S, Buckley NA, et al. Clinical Toxicology. 2026.

10. Gut Decontamination in the Poisoned Patient. — Gosselin S, Hoegberg LCG, Hoffman RS. British Journal of Clinical Pharmacology. 2025.

11. FDA Drug Label. — Updated date: 2024-04-10. Food and Drug Administration.

12. The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations when Benzodiazepine Risks Outweigh Benefits. — Emily Brunner, Chwen-Yuen A. Chen, Tracy Klein, et al American College of Medical Toxicology (2024). 2024.

13. The Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. — Emily Brunner MD DFASAM, Chwen-Yuen A. Chen MD FACP FASAM, Tracy Klein PhD FNP ARNP FAANP FRE FAAN, et al American Society of Addiction Medicine (2025). 2025.